Cytomos Secures $5m to Revolutionise Single-Cell Analysis Technology
Edinburgh-based biotech company Cytomos has announced a significant milestone, raising $5m (approximately £3.98m) in an oversubscribed funding round to scale up the production and sales of its innovative cell analysis technology.
The funding, led by existing investors Archangels and supported by Old College Capital, Scottish Enterprise, and the British Business Bank, comes at a pivotal time for Cytomos as it prepares to accelerate the commercialisation of its first product, Celledonia.
Transforming Drug Discovery with Celledonia
Celledonia, a benchtop cell analyser, is built on Cytomos’ proprietary AuraCyt platform, a groundbreaking technology designed to enhance single-cell analysis.
The company claims Celledonia has the potential to transform biological drug discovery, development processes, and biologics manufacturing. By enabling earlier critical decision-making, the analyser could help bring new therapies to market up to six months faster, while reducing development costs significantly.
Its scalable nature, which measures cellular physiology based on intrinsic single-cell properties, positions it as a unique and valuable tool in the biotech industry.
Scaling Operations and Strengthening the Team
The $5m (approx £3.98m) investment will not only support the commercialisation of Celledonia but also strengthen Cytomos’ operational capacity.
Over the next year, the company plans to expand its 21-person team by adding four new hires. Cytomos is also set to launch a series of trials in collaboration with global partners, reinforcing its commitment to innovation and industry impact.
CEO of Cytomos expressed pride in the team’s efforts, stating that securing this funding amidst challenging market conditions underscores the strength of their vision and execution.
The funding is a huge boost for them. It validates the team’s hard work in delivering their first commercial product and positions them to scale rapidly, establish a presence in the US, and further develop their technology to advance biological drug development and manufacturing automation.
Building the Future of Biotech Innovation
Cytomos’ success in raising $5m (approx £3.98) marks a key step forward in its mission to revolutionise cell analysis and accelerate the pace of drug discovery. With a robust product pipeline, plans to enter the US market, and a growing team, Cytomos is well-positioned to make significant contributions to the biotech industry.
As the company scales up, Celledonia promises to set a new benchmark for efficiency and precision in single-cell analysis, paving the way for faster, more cost-effective therapeutic development.
This achievement not only highlights the potential of Cytomos’ technology but also reinforces Edinburgh’s reputation as a hub for biotech innovation.
News Credits: Cytomos raises $5m to scale up cell analysis technology production
Things you may also like:
- Osivax Begins Phase 2a Clinical Trial for Broad-Spectrum Influenza Vaccine Booster
- Promising Interim Results for AC Immune’s Clinical Trial for Parkinson’s Disease
- MHRA Approves Johnson & Johnson’s Drug for Advanced Bladder Cancer Patients